Dr Christine Bestvina on EGFR Paradigm Shifts & Clinical Trial Equity

In this episode of The OncoloGIST, Dr Christine Bestvina of UChicago Medicine provides a comprehensive look at the rapidly shifting landscape of lung cancer treatment. As molecular diagnostics advance, Dr Bestvina notes that lung cancer has evolved from a single diagnosis into multiple distinct diseases, creating a complex challenge for clinicians striving to stay current with subgroup-specific therapies.

A primary highlight of the discussion is the significant treatment paradigm shift in EGFR-mutated lung cancer. Dr. Bestvina explores the move toward escalated frontline therapy—specifically the combination of chemotherapy plus osimertinib. While moving away from single-agent oral therapy can be a difficult transition, she emphasizes that the improved patient outcomes warrant the additional toxicity of these escalated regimens.

The conversation also addresses the vital push for clinical trial equity. Dr Bestvina advocates for moving trials into community settings, where the majority of frontline patients are treated. She challenges the historical "perfection" required for trial enrollment, arguing that including "real-world" patients—those with comorbidities or a performance status of one—is essential for advancing care that reflects the actual patient population.

Finally, looking ahead to the next year of data, Dr Bestvina shares her "crystal ball" predictions, including:

• KRAS G12C Advancements: Anticipation for the first randomized head-to-head trials (divarasib vs sotorasib or adagrasib) in the second and third-line settings.
• Neoadjuvant Breakthroughs: Long-term data regarding neoadjuvant osimertinib plus chemotherapy, which could redefine how molecular alterations are managed before surgery.